| 1 |
35287697 | Homer1 promotes the conversion of A1 astrocytes to A2 astrocytes and improves the recovery of transgenic mice after intracerebral hemorrhage. | 2022 Mar 14 |
1 |
| 2 |
34247190 | The newly identified MEK1 tyrosine phosphorylation target MACC1 is druggable by approved MEK1 inhibitors to restrict colorectal cancer metastasis. | 2021 Aug |
2 |
| 3 |
31786775 | Anti-inflammatory Effect of AZD6244 on Acrolein-Induced Neuroinflammation. | 2020 Jan |
1 |
| 4 |
32102484 | Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo. | 2020 Feb 24 |
1 |
| 5 |
32358092 | Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer 18F-BMS-986192. | 2020 Dec |
1 |
| 6 |
25326806 | Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. | 2015 Feb |
1 |
| 7 |
25541062 | AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models. | 2015 Mar 1 |
1 |
| 8 |
24448821 | Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model. | 2014 Apr |
1 |
| 9 |
23508762 | Effect of selumetinib on the growth of anastrozole-resistant tumors. | 2013 Apr |
1 |
| 10 |
24132923 | Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. | 2013 Dec 15 |
2 |
| 11 |
22144664 | MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. | 2012 Feb |
2 |
| 12 |
20407895 | Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. | 2011 Feb |
1 |
| 13 |
17237274 | Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. | 2007 Jan |
1 |